Cord blood cells aim to break transfusion dependence in aplastic anemia
NCT ID NCT07499102
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called CK0801 for adults with aplastic anemia who still need blood transfusions after standard therapy. CK0801 uses immune cells from donated cord blood to help the body make its own blood cells again. The trial will check if the treatment is safe and can reduce or stop the need for transfusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug revive blood cell production in children with aplastic anemia?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- A common antioxidant may help platelets recover faster after stem cell transplant
- Could a cancer antibody reboot blood production in aplastic anemia?
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- Promising combo for aplastic anemia trial pulled before start